African Grey Parrot Drug Dosing: A Vet Reference

PublishedMay 12, 2026Reading time6 minExoticRx Editorial

Editorially reviewed against primary literature. Awaiting credentialed clinical reviewer — our editorial process.

The African Grey Parrot (Psittacus erithacus) is one of the longest-lived companion psittacines a clinician will see — birds with verified longevity in the 40–60 year range are not unusual. That timescale matters pharmacologically: a Grey on a chronic NSAID at age twenty is on a drug it may continue to require for two more decades, and the evidence-base for chronic dosing in psittacines is thinner than for any equivalent canine indication. Approach this species with both respect for its longevity and humility about what we don't yet know.

ExoticRx surfaces 234 active dose rules for African Grey Parrots across antibiotics, antifungals, analgesics, anesthetics, and supportive care. Browse the full African Grey formulary for source-cited dose data.

Why avian dosing is its own discipline

A handful of physiological points explain almost every divergence between psittacine and mammalian dosing:

• Air sac respiratory anatomy. Birds have unidirectional through-flow ventilation via parabronchi, with air sacs as bellows. Inhalational anesthetic uptake and elimination are accordingly faster than in mammals, and respiratory pathology can advance silently because birds reserve substantial functional capacity. A Grey that "looks ruffled and quiet" may be in respiratory crisis.
• High metabolic rate. Avian basal metabolic rate runs roughly twice the mammalian allometric prediction, which is why most avian drug intervals are shorter (q12h is more common than q24h for many oral antibiotics). Direct mammalian extrapolation chronically under-doses parrots.
• Renal portal system. Like reptiles, birds have a renal portal system: drugs delivered via the leg or caudal half of the body may pass through the kidneys before reaching systemic circulation. This is most clinically relevant for nephrotoxic drugs — give them in the pectoral muscle or via IV, never in the leg.
• Plasma protein binding differences. Several drugs (notably Doxycycline, Itraconazole) have distinct binding kinetics in birds compared to mammals, justifying dose adjustments.

Antibiotic priorities

Two infectious diseases drive the bulk of avian antibiotic prescribing in pet parrots: chlamydiosis (Chlamydia psittaci, zoonotic) and bacterial enteritis or septicaemia (most often gram-negative, sometimes secondary to husbandry-driven immunosuppression).

• Doxycycline — first-line for chlamydiosis. The standard treatment course is long (typically 45 days) to clear the intracellular reservoir; shorter courses are associated with relapse. Both oral and injectable preparations are used; the long-acting injectable form is invaluable in patients who refuse oral medication. Always counsel owners on the zoonotic risk.
• Enrofloxacin / Marbofloxacin / Ciprofloxacin — fluoroquinolones; first-line for many gram-negative infections in psittacines. Note historical concerns about cartilage toxicity in juvenile birds and rare hepatic effects with prolonged courses.
• Amikacin — reserved for severe gram-negative or resistant infections. Nephrotoxic; pre-treatment hydration mandatory, pectoral muscle administration only.
• Ceftazidime — useful for Pseudomonas coverage; injectable.
• Clindamycin — anaerobic coverage. Note that, unlike rabbits, oral clindamycin is acceptable in psittacines; gut flora architecture differs.
• Trimethoprim-Sulfamethoxazole — broad-spectrum oral, useful for less-severe disease.
• Tylosin — historical use in avian respiratory disease, less common now.

Always submit a culture where clinical signs allow waiting; empirical fluoroquinolone use is reasonable in the unstable patient but should be revised to a culture-guided choice as soon as data return.

Antifungal disease: the underdog killer

Fungal disease is at least as common as bacterial disease in pet parrots and is far more frequently missed. The two main pathologies:

• Aspergillosis — Aspergillus fumigatus most common; air-sacculitis, granulomatous nodules, syringeal disease. Itraconazole is the historical standard, though hepatotoxicity is a real concern in Greys (parrots in this genus are unusually susceptible).
• Candidiasis — generally a sequel to oral antibiotic therapy, immunosuppression, or hand-feeding errors in young birds. Crop and proventricular disease most common.

Drugs in routine use:

• Itraconazole — first-line for aspergillosis. Important: African Greys (and several other psittacines) are reported to be hepatotoxic-prone with itraconazole at standard avian doses. Use lower doses, monitor liver enzymes (bile acids, AST), and consider voriconazole as a primary alternative.
• Voriconazole — often preferred over itraconazole for aspergillosis in Greys for the reason above. PK varies considerably between psittacines; therapeutic drug monitoring is increasingly recommended.
• Fluconazole — narrower spectrum; useful for Candida but limited activity against Aspergillus.
• Amphotericin B — reserved for severe disease; nebulised forms used adjunctively in air-sac aspergillosis.

Analgesia and anesthesia

Pain assessment in psittacines remains imperfect, but the literature on avian opioid receptor distribution (kappa-predominant, with limited mu-receptor expression in many species) strongly supports the choice of butorphanol as a more reliable analgesic than the pure mu-agonists in birds.

• Butorphanol — kappa-agonist; widely used as primary analgesic in avian medicine because of the receptor distribution above. This is one of the few species classes where butorphanol genuinely outperforms buprenorphine for procedural analgesia.
• Buprenorphine — partial mu-agonist; less reliable in many psittacines on receptor-distribution grounds, but used in some protocols.
• Meloxicam — NSAID; widely used. Avian-specific PK supports relatively short dosing intervals (typically q12–24h depending on the species and indication). Dehydration and nephropathy are absolute contraindications — fluid status before any NSAID course.
• Tramadol — used in some chronic pain protocols.
• Gabapentin — emerging use for neuropathic and chronic pain.

For anesthesia:

• Isoflurane — standard volatile agent; rapid induction and recovery in birds. Mask induction is well-tolerated in most psittacines unlike rabbits.
• Propofol — IV induction; useful but apnea is common. Have intubation supplies and a positive-pressure ventilation plan before you induce.

Supportive care

• Aggressive thermal support and fluid therapy — a sick bird is almost always cold and dehydrated. Restore both before pursuing any aggressive diagnostics.
• Calcium (oral/injectable) — relevant for hypocalcaemic Greys (a recognised syndrome in this species; Greys appear unusually predisposed to dietary hypocalcaemia despite adequate dietary intake on paper).
• Vitamin K1 — anticoagulant rodenticide exposure or hepatic dysfunction.
• Nutritional support — gavage feeding via crop tube is well-tolerated and is often the single highest-impact intervention in a sick parrot.

Common dosing mistakes

1. Treating like a small mammal. Avian metabolic rate justifies shorter intervals than the equivalent mammalian protocol. Once-daily dosing of a drug listed q12h in the avian formulary is a recurring under-dosing pattern.
2. Failing to use the pectoral muscle for nephrotoxic drugs. Caudal injection sites engage the renal portal system. This is well-known in academic avian medicine and consistently surprising to general-practice clinicians who try a leg injection because it is technically easier.
3. Defaulting to itraconazole in Greys. As above — this species (and the closely related Timneh) is documented as more hepatotoxic-prone than the average psittacine. Default to voriconazole, monitor liver enzymes, and counsel owners on the risk if itraconazole is the only available option.
4. Under-dosing analgesia. A bird that has stopped vocalising and is sitting fluffed at the bottom of the cage is severely sick and almost certainly in pain. Birds mask pain ferociously; do not assume a quiet patient is a comfortable one.

Sources

• Carpenter's Exotic Animal Formulary, current edition (avian sections)
• BSAVA Manual of Psittacine Birds
• Avian Medicine: Principles and Application (Ritchie, Harrison, Harrison)
• Peer-reviewed avian PK and clinical literature
• Antimicrobial-resistance and chlamydiosis treatment consensus literature

Each drug page above carries a source citation alongside its evidence level and dose range.

Disclaimer

This article is an informational reference for licensed veterinary professionals, technicians, and students. It does not constitute veterinary medical advice and is not a substitute for clinical judgement, current peer-reviewed literature, or the recommendation of an attending clinician. See the full dosage disclaimer.